MARKET

ACRX

ACRX

Acelrx Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.770
-0.040
-2.21%
After Hours: 1.770 0 0.00% 16:07 01/22 EST
OPEN
1.810
PREV CLOSE
1.810
HIGH
1.850
LOW
1.770
VOLUME
613.48K
TURNOVER
--
52 WEEK HIGH
4.090
52 WEEK LOW
1.640
MARKET CAP
140.84M
P/E (TTM)
-2.6473
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of ACRX and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

ACRX News

  • AcelRx Pharmaceuticals (ACRX) Stock Sinks As Market Gains: What You Should Know
  • Zacks.01/13 22:50
  • AcelRx +4% premarket on corporate update
  • Seeking Alpha - Article.01/13 13:40
  • AcelRx Sees Prelim. FY19 Sales $2.3M, Cash, Cash Equivalents And Short-Term Investments Of $66.1M As Of Dec. 31
  • Benzinga.01/13 12:18
  • AcelRx Announces Year-End 2019 Metrics and Provides Corporate Updates
  • PR Newswire.01/13 12:00

More

Industry

Biotechnology & Medical Research
+0.11%
Pharmaceuticals & Medical Research
-0.21%

Hot Stocks

Name
Price
%Change

About ACRX

AcelRx Pharmaceuticals, Inc. is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain. Its lead product candidates include ARX-04, Zalviso, which utilize sublingual sufentanil, delivered through a non-invasive route of administration, and ARX-03. ARX-04 is meant for the treatment of moderate-to-severe acute pain to be administered by a healthcare professional to a patient in medically supervised settings. Zalviso is meant for the management of moderate-to-severe acute pain in hospitalized adult patients. ARX-03 provides mild sedation, anxiety reduction and pain relief for patients undergoing painful procedures in a physician's office. It also includes ARX-02, which is meant for the treatment of patients who suffer from breakthrough pain (BTP) due to cancer.
More

Webull offers AcelRx Pharmaceuticals Inc (ACRX) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.